Element of the virus responsible for inflammation in viral keratoconjunctivitis isolated

Article

Researchers in the Howe Laboratory, Department of Ophthalmology of the Massachusetts Eye and Ear Infirmary and Harvard Medical School, and in the University of Oklahoma Health Sciences Center, have used a novel model to determine what part of the virus is responsible for the inflammation in viral keratoconjunctivitis

Researchers in the Howe Laboratory, Department of Ophthalmology of the Massachusetts Eye and Ear Infirmary and Harvard Medical School, and in the University of Oklahoma Health Sciences Center, have used a novel model to determine what part of the virus is responsible for the inflammation in viral keratoconjunctivitis.

Using a unique mouse model of adenovirus keratitis, Dr Chodosh and his team studied the role of viral components in the cornea to determine which viral part(s) induce an innate immune response. The authors found that neither viral DNA nor viral gene expression was necessary for inflammation. In contrast, viral capsid, the protein coat of the virus, induced inflammation similar to intact virus. Mice lacking the toll-like receptor 9 molecule, which acts as a pathogen DNA-sensing molecule within the cell, developed clinical inflammation upon adenovirus infection similar to wild type mice. Virus associated inflammation in the mouse cornea could be blocked by a treatment with a peptide containing components of the adenoviral capsid. Adenovirus infection of the cornea induces inflammation principally through contact between the viral capsid and the host cell.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.